Heijl Anders, Bengtsson Boel, Chauhan Balwantray C, Lieberman Marc F, Cunliffe Ian, Hyman Leslie, Leske M Cristina
Department of Ophthalmology, Lund University, Malmö University Hospital, Malmö, Sweden.
Ophthalmology. 2008 Sep;115(9):1557-65. doi: 10.1016/j.ophtha.2008.02.005. Epub 2008 Apr 18.
Three major glaucoma trials, all using the same Humphrey visual field tests, specified different criteria to define visual field progression. This article compares the performance of these criteria with a reference standard of unanimous classifications by 3 independent glaucoma experts.
Longitudinal, comparative study of diagnostic criteria.
Two hundred forty-five patients with manifest glaucoma in the Early Manifest Glaucoma Trial (EMGT).
Visual field series of 1 eye of each of 245 EMGT patients were classified by 3 independent glaucoma specialists as definitely progressing, definitely nonprogressing, or neither. Field series that were classified in the first 2 categories by all 3 experts met the reference standards for the progressing and nonprogressing groups and were analyzed according to the progression criteria of the Advanced Glaucoma Intervention Study (AGIS), the Collaborative Initial Glaucoma Treatment Study (CIGTS), and the EMGT. Sensitivity, specificity, time to progression, and sustainability were calculated.
Progression, nonprogression, sensitivity, specificity, time to progression, and sustainability.
Seventy-seven field series were definitely progressing, and 95 series were definitely nonprogressing. Among progressing eyes, 45 (58%) of 77 were identified using AGIS criteria, 58 (75%) of 77 were identified with CIGTS criteria, and 74 (96%) of 77 were identified with EMGT criteria; all comparisons of sensitivities were significant, simultaneous (P<0.001), and pairwise (P<0.01). The specificity for EMGT criteria was 89%, lower (P<0.05) than that of AGIS (98%) and CIGTS (99%) criteria. Median time to progression was considerably shorter with EMGT criteria (33 months; 95% confidence interval [CI], 30-36 months) than with AGIS (66 months; 95% CI, 57-78 months) and CIGTS (55 months; 95% CI, 48-66 months) criteria. Sustainability increased with time after progression; it averaged 79%, 84%, and 81%, respectively, for AGIS, CIGTS, and EMGT criteria during the first year after the first progression and 95%, 100%, and 93% during the fourth year after progression.
The EMGT criteria identified progression earlier and more often than AGIS and CIGTS criteria. Specificity was good for all criteria but was better with AGIS and CIGTS than with EMGT criteria. Sustainability was high for all 3 sets of criteria and best for CIGTS criteria and increased with time after progression.
三项主要的青光眼试验均采用相同的汉弗莱视野测试,但规定了不同的标准来定义视野进展。本文将这些标准的性能与由3名独立青光眼专家进行一致分类的参考标准进行比较。
诊断标准的纵向比较研究。
早期显性青光眼试验(EMGT)中的245例显性青光眼患者。
245例EMGT患者中每例患者的1只眼睛的视野系列由3名独立的青光眼专家分类为明确进展、明确无进展或两者皆非。所有3名专家在前两类中分类的视野系列符合进展组和无进展组的参考标准,并根据高级青光眼干预研究(AGIS)、协作性初始青光眼治疗研究(CIGTS)和EMGT的进展标准进行分析。计算敏感性、特异性、进展时间和可持续性。
进展、无进展、敏感性、特异性、进展时间和可持续性。
77个视野系列明确进展,95个系列明确无进展。在进展的眼中,77只眼中有45只(58%)根据AGIS标准被识别,77只眼中有58只(75%)根据CIGTS标准被识别,77只眼中有74只(96%)根据EMGT标准被识别;敏感性的所有比较均具有显著的同时性(P<0.001)和两两比较(P<0.01)。EMGT标准的特异性为89%,低于AGIS(98%)和CIGTS(99%)标准(P<0.05)。与AGIS(66个月;95%置信区间[CI],57-78个月)和CIGTS(55个月;95%CI,48-66个月)标准相比,EMGT标准的进展中位时间明显更短(33个月;95%CI,30-36个月)。进展后的可持续性随时间增加;在首次进展后的第一年,AGIS、CIGTS和EMGT标准的平均可持续性分别为79%、84%和81%,在进展后的第四年分别为95%、100%和93%。
与AGIS和CIGTS标准相比,EMGT标准更早且更频繁地识别出进展。所有标准的特异性都较好,但AGIS和CIGTS标准比EMGT标准更好。所有3套标准的可持续性都很高,CIGTS标准最佳,且在进展后随时间增加。